Vaccine development for emerging infectious diseases Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics can offer critical lessons to prepare for future public health emergencies. Nature Medicine

Examination of the vaccine strategies and technical platforms used for the COVID-19 pandemic in the context of those used for previous emerging and reemerging infectious diseases and pandemics may offer some mutually beneficial lessons.

Ginger Eatman thought she was safe after getting her second COVID-19 vaccination in February. But she kept wearing her mask, using hand sanitizer and wiping down the carts at the grocery store anyway. A few weeks later, she noticed a scratchy throat.

"By Wednesday morning, St. Patrick's Day, I was sick. I had congestion — a lot of congestion — and some coughing," says Eatman, 73, of Dallas, Ga.

Her doctor thought her symptoms might be allergies. But Eatman started feeling sicker. And then she suddenly lost her sense of smell. ...

So Eatman got tested for the coronavirus. It came back positive. ...

Eatman isn't alone in this experience. It's a long-recognized phenomenon called "vaccine breakthrough."

Regeneron says its antibody cocktail injection prevents Covid In previous studies, antibodies had to be given intravenously. This one can be given with an under-the-skin injection. Matthew Herper STAT

Regeneron Pharmaceuticals said Monday that a single administration of its monoclonal antibody cocktail reduced the risk that volunteers exposed to Covid-19 would develop the disease by 81%.